FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Swisher Daniel N JR 		2. Issuer Name and Ticker or Trading Symbol

SUNESIS PHARMACEUTICALS INC [ SNSS ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
President and CEO
(Last)          (First)          (Middle)

C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., STE. 400 		3. Date of Earliest Transaction (MM/DD/YYYY)

7/10/2017
(Street)

SOUTH SAN FRANCISCO, CA 94080
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy)   $93.24   7/10/2017     D         4306      (1) 9/13/2017   Common Stock   4306     (2) 0   D    
Employee Stock Option (right to buy)   $17.64   7/10/2017     D         18333      (1) 8/31/2019   Common Stock   18333     (2) 0   D    
Employee Stock Option (right to buy)   $12.54   7/10/2017     D         118435      (1) 6/30/2021   Common Stock   118435     (2) 0   D    
Employee Stock Option (right to buy)   $10.44   7/10/2017     D         70834      (1) 2/28/2022   Common Stock   70834     (2) 0   D    
Employee Stock Option (right to buy)   $31.32   7/10/2017     D         50000      (1) 2/28/2023   Common Stock   50000     (2) 0   D    
Employee Stock Option (right to buy)   $39.30   7/10/2017     D         50001      (1) 2/28/2024   Common Stock   50001     (2) 0   D    
Employee Stock Option (right to buy)   $10.20   7/10/2017     D         50000      (1) 10/31/2024   Common Stock   50000     (2) 0   D    
Employee Stock Option (right to buy)   $2.62   7/10/2017     A      17582         (3) 7/10/2027   Common Stock   17582     (2) 17582   D    
Employee Stock Option(right to buy)   $2.62   7/10/2017     A      240177         (4) 7/10/2027   Common Stock   240177     (2) 240177   D    

Explanation of Responses:
(1)  The option grant provided for vesting in monthly installments over four (4) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company.
(2)  On July 10, 2017, the issuer canceled, pursuant to the issuer's option exchange program, the following options: (1) an option granted on 9/13/07 for 4,306 shares; an option granted on 8/31/09 for 18,333 shares; an option granted on 6/30/11 for 118,435 shares; an option granted on 2/29/12 for 70,834; an option granted on 2/28/13 for 50,000 shares; an option granted on 2/28/14 for 50,001 shares and option granted on 10/31/14 for 50,000 shares. In exchange, the reporting person received two replacement options, one for an aggregate of 17,582 shares, and another replacement option for an aggregate of 240,177 shares, each having an exercise price of $2.62 a share.
(3)  The option vests in monthly installments over three (3) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company.
(4)  The option vests in monthly installments over two (2) years measured from the option grant date, provided that at each such vesting date, the reporting person shall then be providing service (as defined in the Option Plan) to the Company.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Swisher Daniel N JR
C/O SUNESIS PHARMACEUTICALS, INC.
395 OYSTER POINT BLVD., STE. 400
SOUTH SAN FRANCISCO, CA 94080 		X
President and CEO

Signatures
/s/ Daniel N. Swisher, Jr. 7/12/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Sunesis Pharmaceuticals Charts.
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Sunesis Pharmaceuticals Charts.